To identify noninvasive diagnostic biomarkers for membranous nephropathy (MN).
Background
Membranous nephropathy (MN) is one of the commonly diagnosed kidney diseases, with the incidence rate increased by more than 2 times from 2003 to 2014 in China [1] . It is estimated that approximately 20% of patients with MN will progress to end stage renal disease and 10% of them will die within 5 to 10 years [2, 3] . Thus, accurate and timely diagnosis is required to prevent possible progression and improve patient outcomes.
Currently, renal biopsy and histological evaluation remain as the standard procedure for diagnosis of MN. However, renal biopsy is invasive, which may cause some unanticipated complications in the patients at high risk [4, 5] . Hence, there is an urgent need to identify some noninvasive diagnostic biomarkers for MN.
The majority of MN is idiopathic (IMN) and the remainder is secondary to systemic autoimmune disease, certain malignancies, infections, or exposure to environmental factors [6] . Previous studies have shown that circulating autoantibodies against the M-type phospholipase A2 receptor (anti-PLA2R) are detectable in 80% of IMN patients and thus serum anti-PLA2R has been widely accepted as a biomarker for clinical diagnosis of IMN [7] . The coincidence rate of serum anti-PLA2R antibody and PLA2R in kidney tissue has been demonstrated to be 100% [8] . The remainder of MN cases may be associated with the inflammatory state [9] and therefore several circulatory immune cells and inflammatory cytokines have also been suggested as biomarkers for secondary MN. For example, Zhang et al. detected that concentrations of serum interleukin (IL)-2, IL-4, IL-10, IL-17A, and interferon (IFN)-g were higher in the MN patients compared to controls [10] . Liu et al. observed the percentages of CD38(+) CD19(+), IL-10(+) CD19(+) B cells, and serum IL-10 level in MN patients were significantly higher than in health controls. The percentage of CD38(+) CD19(+) was positively correlated with the 24-hour urine protein concentration and negatively correlated with the value of estimated glomerular filtration rate (eGFR), which was the opposite with IL-10(+) CD19(+) B cells and serum IL-10 level [11] . Nagasawa et al. [12] used DNA microarray analysis to search peripheral blood mononuclear cells (PBMCs) mRNA for genes that had expression levels that distinguished between patients with MN and healthy volunteers. They proposed that IFN-alpha-inducible protein 27 in the peripheral blood could serve as a noninvasive marker for MN diagnosis. However, the clinical applications remain rare and further studies are still needed to investigate novel biomarkers for MN.
MicroRNAs (miRNAs) are a class of small noncoding RNA that negatively regulate gene expression by translational repression or induction of messenger RNA degradation.
Recently, miRNAs have been found to be implicated in the development of nephropathy by influencing the inflammatory related genes [13, 14] and thus they may also be underlying biomarkers for MN. This hypothesis was demonstrated in the study of Li et al. that found miR-217 regulated the expression of TNF superfamily member 11 (TNFSF11). Compared with control patients, miR-217 was significantly downregulated and TNFSF11 was significantly upregulated in MN patients. The patients with MN and the control patients could then be obviously separated according to the expression of miR-217, with an area under the curve of 0.941, and sensitivity and specificity of 88.9% and 75.9% respectively [13] . However, miRNA biomarkers for diagnosis of MN remain rarely reported [15] .
The goal of this study was to further screen inflammatory related miRNA-mRNA biomarkers in both blood and urine samples for MN by using the microarray datasets downloaded from a public database. The miRNA-mRNA interaction and their function were also investigated. Our study may provide more noninvasive diagnostic biomarkers for MN.
Material and Methods

Data collection
The mRNA microarray data under accession number GSE73953 contributed by Nagasawa et al. [12] was downloaded from the Gene Expression Omnibus (GEO) repository at the National Center for Biotechnology Information (NCBI) (www.ncbi.nlm. nih.gov/geo) based on the platform of GPL4133 Agilent-014850 Whole Human Genome Microarray 4x44K G4112F. This dataset consisted of 25 PBMCs samples from 8 MN patients and 2 pooled healthy participants.
The miRNA expression profile under accession number GSE64306 deposited by Wang et al. [16] was also downloaded from GEO on the basis of the platform of GPL19117 [miRNA-4] Affymetrix Multispecies miRNA-4 Array. The miRNA expression analysis was performed in urine sediments from 4 MN patients and 6 healthy participants.
Data preprocessing and differential expression analysis
The raw CEL files were preprocessed and normalized using the Robust Multichip Average (RMA) algorithm [17] in the R Bioconductor affy package (version 3.4.1; http://www.bioconductor.org/packages/release/bioc/html/affy.html). The differentially expressed genes (DEGs) and the differentially expressed miRNAs (DEMs) between MN patients and controls were screened using the linear models for microarray data (LIMMA) method [18] [19] to observe whether the use of DEGs and DEMs could distinguish the MN patients from the controls.
PPI network and module analyses
Protein-protein interaction (PPI) pairs were predicted by the Search Tool for the Retrieval of Interacting Genes (STRING, version 10.0; http://www.string-db.org/) [20] . Then, the PPI network of DEGs was constructed using Cytoscape software (version 3.4; www.cytoscape.org/) [21] based on the obtained PPI pairs. In the PPI network, the node score was calculated based on degree centrality. The node with the high score, which likely played an important role in the PPI network, was referred to as the hub protein. Following PPI network analysis, the significant modules were identified from the PPI network using the Molecular Complex Detection (MCODE; version 1.4.2, http:// apps.cytoscape.org/apps/mcode) [22] plugin in the Cytoscape software [21] with degree cutoff ³2 and k-core ³3.
miRNA-target gene regulatory analysis
The target genes of DEMs were predicted using an online resource, miRDB (version 1.0; http://mirdb.org) [23] . Subsequently, the DEMs-target gene regulatory network was also constructed using Cytoscape software [21] . The DEGs identified in GSE73953 and the target genes of DEMs identified in GSE64306 were integrated to obtain the intersection genes between PBMCs and urine sediments samples.
Functional enrichment analyses
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Functional enrichment analyses for DEGs in PMBCs samples
The upregulated DEGs were significantly enriched into 10 KEGG pathways (including Prion diseases, CCL5) and 43 GO biological process terms (including negative regulation of neuron apoptotic process, BAX), while the downregulated DEGs were significantly enriched into 12 KEGG pathways (including hsa04010: MAPK signaling pathway, PPM1A; hsa04115: p53 signaling pathway, CDK1), and 20 GO biological process terms (Table 2) .
PPI network and module analyses for DEGs in PMBCs samples
A total of 621 PPI pairs (i.e., CDK1-RAB1A), were predicted from the DEGs, which were then used for constructing the PPI network, including 329 nodes (Figure 2 ). The hub proteins in the PPI network were screened by calculating the degree. The results ( Figure 3) showed CDK1 (degree=18), CCL5 (degree=12), and MAPK11 (degree=8) may be crucial genes for MN.
From the PPI network, 3 significant modules were screened ( Figure 4 ). Functional enrichment analyses revealed that the genes in module 2 were involved in hsa04062: chemokine signaling pathway (CCL5) and hsa04060: cytokine-cytokine receptor interaction (CCL5) ( Table 3) .
DEMs identification
A total of 28 DEMs, including 21 upregulated (including hsa-miR-214-3p, hsa-miR-192-3p, hsa-miR-20a-5p, and hsa-miR-195-5p) and 7 downregulated miRNAs (including hsa-miR-328-5p), were identified between urine sediments of MN patients and controls (Table 1) . Heat map analysis showed that the MN group and the control group were also well distinguished by the DEMs ( Figure 1B ).
miRNA-target gene regulatory network analysis for DEMs
Using the miRDB database, 276 target genes of DEMs were predicted. The DEMs-target gene regulatory network was constructed as shown in Figure 5 , with the miR-30e-5p, miR-195-5p, and miR-20a-5p regulating more target genes.
Functional enrichment analyses for DEMs
The functions of the target genes of DEMs were predicted by GO and KEGG enrichment analyses using DAVID. As shown in Table 4 , these target genes were significantly enriched in 26 GO terms, such as cell cycle arrest (PPM1A), intracellular signal transduction (BRSK1), protein phosphorylation (BRSK1), and establishment of cell polarity (BRSK1).
Integrated analysis of 2 datasets
A total of 13 intersection genes were identified between DEGs in PMBCs and the target genes of DEMs in urine sediments, such as RFX7, MBNL3, SEC24C, FBXO32, ZNF800, ZNF532, RAB1A, AKTIP, SLC13A3, PPM1A, CNOT6L, PCMT1, and BRSK1 (Table 5 ). Among them, hsa-miR-214-3p-SEC24C, hsa-miR-192-3p (upregulated)-RAB1A (downregulated), hsa-miR-20a-5p (upregulated)-AKTIP (downregulated), hsamiR-195-5p (upregulated)-SLC13A3 (downregulated), hsa-miR-195-5p (upregulated)-PPM1A (downregulated), and hsa-miR-328-5p (downregulated)-BRSK1 (upregulated) were negatively related in their expression level (Table 1) .
Discussion
By integrating the mRNA expression profile data in PBMCs and miRNA expression profile data in urine sediments, our present study suggests that hsa-miR-195-5p, hsa-miR-192-3p, hsa-miR-328-5p, and their target genes PPM1A, RAB1A, and BRSK1 may be crucial biomarkers for the diagnosis and development of MN. PPM1A and BRSK1 may be involved in MN by participating in the MAPK related signaling pathway, while RAB1A may also be associated with MN by involving the p53 signaling pathway (CDK1-RAB1A).
Accumulating evidence has demonstrated that the MAPK pathway is frequently activated in nephropathy. Activated p38 MAPK mediates apoptosis of glomerular podocytes by increasing the Bax/Bcl-2 ratio [27, 28] . Furthermore, activated extracellular signal-regulated kinase (ERK1/2) and p38 MAPK were also reported to induce an increase in the activity of nuclear factor-kappaB (NF-kB) and produce the expression of several pro-inflammatory cytokines, such as IL-6, IL-1, tumor necrosis factor (TNF)-alpha, and IL-17, resulting in renal injury, which could be reversed by their inhibitors [29, 30] . Thus, inhibition of the MAPK signaling pathway has been suggested as an underlying treatment approach for nephropathy. This hypothesis has been investigated in several studies. GRM8  FFAR3  F2R  CYSLTR1  CXCR6  CXCR3  CCL5  C3AR1  AAPLNR  ADRA2C  RPS21  RPS12  RPS13  RPL36  RPL35A  RPL18A  RPL13A  PPP2CA  HDAC3  RPL15  NFKB1  EIF4G1  CDK1  PLCB3  PMCH  NPSR1  GPR17  LPAR1  JUN  PIK3CA   10  15  20 Malik et al. observed the use of apigenin ameliorated streptozotocin-induced diabetic nephropathy in rats via preventing the activation of the MAPK pathway, which then inhibited inflammation (reduced TNF-a, IL-6, and NF-kB expression) and apoptosis (increased expression of Bcl-2 and decreased Bax and caspase-3) [32] . Similarly, pretreatment with galangin preserved renal function (normalized serum creatinine and blood urea nitrogen), suppressed oxidative stress (decreased level of malondialdehyde), inflammation (reduced levels of TNF-a and IL-6), and the activation of apoptotic pathways (decreased expression of Bax and caspase-3) by de-phosphorylating p38, JNK, and ERK1/2 proteins [33] . In our study, MAPK11, MAPK15
as well as pro-inflammatory cytokine CCL5 and pro-apoptotic Bax were also found to be significantly upregulated in MN, further verifying the MAPK-mediated inflammation and apoptosis mechanisms for MN. In addition, a recent study found that PPM1A could negatively regulate ERK by directly dephosphorylating its pT position early in epidermal growth factor stimulation [34] . Using a functional genomic approach, PPM1A was shown to dephosphorylate IKKb at Ser177 and Ser181 and terminate IKKb-induced NF-kB activation, leading to inflammation suppression [35] . inflammatory (M1) macrophages and promoted the production of inflammatory cytokines [36] . Thus, PPM1A may be hypothesized to be downregulated and promote the development of MN by MAPK-mediated inflammation and apoptosis, which was preliminarily proved in our study. However, there was no study to confirm the roles of PPM1A in MN, and thus, further experiments are required. Furthermore, the study of Wang et al. revealed that the expression of BRSK1 was decreased in breast cancer cell lines, and treatment of PI3K inhibitor LY294002 could increase BRSK1 expression, implying BRSK1 may function as a cell apoptosis promotor via PI3K-Akt signaling pathway. Generally, there is crosstalk between the MAPK pathway and the PI3K pathways that plays a role in diseases [37] . Therefore, BRSK1 may also be involved in the MAPK pathway as well as other genes (i.e., MAPK6, MAP3K2, and MAP3K1) enriched in protein phosphorylation. As expected, our study showed BRSK1 was upregulated in MN patients and may cause the apoptosis of glomerular podocytes.
Although the RAB1A gene was not enriched into any pathway or GO term in our study, it could interact with CDK1 as seen from the PPI analysis and hereby we speculate that RAB1A may play important roles in MN by participating in the p53 signaling pathway which was CDK1 enriched. CDK1 encodes a cyclin kinase that associates with cyclin to control cell cycle transition from G1 to S and promote cell proliferation [38] . Thus, CDK1 may be downregulated in nephropathy [39] ; this was also demonstrated by our study in the MN group. Due to interaction with CDK1, RAB1A may also be downregulated in MN as our study reported.
This suggested finding can be indirectly demonstrated by other recent studies: Liu et al. found RAB1A was significantly lower in aging renal glomerular mesangial cells [40] .
In addition to genes, miRNAs have also been suggested as key biomarkers in MN [13, 15, 41] . Thus, we also investigated the DEMs in urine sediments of MN patients. In line with the expression in the peripheral blood samples of MN patients [41] and amniotic fluid exosomes from fetuses with congenital hydronephrosis [42] , our results also showed miR-195-5p was high expressed in urine sediments of MN patients. Transfection with miR-195 has been reported to reduce the protein levels of BCL2 and contribute to podocyte apoptosis via an increase in caspase-3 [43] , while the use of miRNA-195 inhibitor protected mesangial cells from apoptosis and promoted cellular proliferation in vitro [44] . In accordance with these findings, our results also suggested miR-195 could negatively regulate PPM1A which was pro-inflammatory and pro-apoptotic when downregulated as we described. However, the relationship between miR-195 and PPM1A has never been validated in in vitro or in vivo experiments, and thus needs further investigation. Previously, miR-192 has been reported to be a potential biomarker of ischemia-reperfusion-induced kidney injury because of its increased expression in plasma and urine [45, 46] . Also, its high expression has been demonstrated to be associated with the activation by p53 [47] , while p53 upregulation suppressed the expression of CDK1 [48] and may also block RAB1A. In accordance with these aforementioned studies, we also found hsa-miR-192-3p was upregulated and could negatively regulate the expression of its target gene RAB1A. However, the relationship between miR-192-3p and RAB1A has never been validated in in vitro or in vivo experiments, and thus needs further investigation. MiR-328-5p was observed to be downregulated in pressure-induced renal fibrosis and it may function by upregulating its target gene CD44 expression [49] . Renal fibrosis is a pathological characteristic of advanced MN and therefore miR-328-5p may also be downregulated in MN, which was shown to be the case in our study. There have been no studies that have indicated a negative relationship between miR-328 and BRSK1 in MN, which was thus a novel result in our study.
Conclusions
Our study revealed that miR-195-5p, miR-192-3p, miR-328-5p, and their target genes PPM1A, RAB1A, and BRSK1 in peripheral blood and urine samples may be potential biomarkers for MN. Further clinical and experimental studies are needed to verify the diagnosis accuracy and interaction mechanism.
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